(Q37153031)

18 August 2017

1 reference

title

Cardiovascular disease and modifiable cardiometabolic risk factors (English)

1 reference

18 August 2017

main subject

cardiovascular disease

1 reference

Christopher P Cannon

1

1 reference

18 August 2017

publication date

1 January 2007

1 reference

18 August 2017

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

11-28

1 reference

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Challenges associated with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

A potential decline in life expectancy in the United States in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Defining obesity cut points in a multiethnic population

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

The link between abdominal obesity, metabolic syndrome and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Obesity and diabetes in the developing world--a growing challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Increasing Trends in Incidence of Overweight and Obesity over 5 Decades

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Obesity and workers' compensation: results from the Duke Health and Safety Surveillance System

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Obesity — The New Frontier of Public Health Law

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Therapeutic options for modifying cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Abdominal adiposity and coronary heart disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Drug treatment of the overweight patient

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Cardiovascular protection using beta-blockers: a critical review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Standards of medical care in diabetes--2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Metabolic syndrome: is it a syndrome? Does it matter?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Advanced glycation endproducts: what is their relevance to diabetic complications?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Impact of a program to improve adherence to diabetes guidelines by primary care physicians

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

New and emerging strategies for reducing cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

The role of endocannabinoid system blockade in the treatment of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980025-1

7 January 2021

10.1016/S1098-3597(07)80025-1

Identifiers

DOI

1 reference

18 August 2017

1 reference